Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial

Mazieres, JulienJulienMazieresPaik, Paul KPaul KPaikGarassino, Marina CMarina CGarassinoLe, XiuningXiuningLeSakai, HiroshiHiroshiSakaiVeillon, RemiRemiVeillonSmit, Egbert FEgbert FSmitCortot, Alexis BAlexis BCortotRaskin, JoJoRaskinViteri, SantiagoSantiagoViteriWu, Yi-LongYi-LongWuCHIH-HSIN YANGAhn, Myung-JuMyung-JuAhnMa, RuiRuiMaZhao, JunJunZhaoO'Brate, AuroraAuroraO'BrateBerghoff, KarinKarinBerghoffBruns, RolfRolfBrunsOtto, GordonGordonOttoJohne, AndreasAndreasJohneFelip, EnriquetaEnriquetaFelipThomas, MichaelMichaelThomas2023-10-032023-10-032023-09-012374-2437https://scholars.lib.ntu.edu.tw/handle/123456789/635919MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non-small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches.en[SDGs]SDG3Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trialjournal article10.1001/jamaoncol.2023.1962372706982-s2.0-85172034787https://api.elsevier.com/content/abstract/scopus_id/85172034787